Keyword: Insys Therapeutics
In an Insys Therapeutics case that’s already full of shocking details, prosecutors just upped the ante.
During Insys founder John Kapoor's criminal trial, prosecutors played a video urging sales reps to break the rules when promoting its opioid Subsys.
The U.S. Senate has released a report on Insys that provides an insider’s view of a company leaning on physicians to help drive sales.
The $150 million is in line with Insys' previous estimate, and the final deal could include contingency-based payments of up to $75 million.
Doctors who got free meals, speaking fees and other payments from drugmakers also prescribed more opioids, a new analysis found.
Newly unsealed court documents allege Insys provided incentives for off-label prescribing of its painkiller Subsys.
The feds charged five doctors over accepting Insys' bribes and said they've secured cooperation from two former employees.
In what may be the first foray by Big Pharma into the sale of medical marijuana products, Novartis has struck a deal with a Canadian company that sells medical cannabis products.
Drugmakers contributed more than $10 million to organizations and affiliated individuals that backed wide opioid use, a senator's investigation found.
Lawyers for former Insys sales executive Jeffrey Pearlman asked the court to censure the term "opioid crisis" during his kickbacks trial.